Moleculin Biotech (Moleculin Biotech) Ending Cash Position : $23.55 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Ending Cash Position?

Moleculin Biotech's Ending Cash Position for the quarter that ended in Dec. 2023 was $23.55 Mil.

Moleculin Biotech's quarterly Ending Cash Position declined from Jun. 2023 ($32.17 Mil) to Sep. 2023 ($24.58 Mil) and declined from Sep. 2023 ($24.58 Mil) to Dec. 2023 ($23.55 Mil).

Moleculin Biotech's annual Ending Cash Position declined from Dec. 2021 ($70.90 Mil) to Dec. 2022 ($43.15 Mil) and declined from Dec. 2022 ($43.15 Mil) to Dec. 2023 ($23.55 Mil).

Moleculin Biotech Ending Cash Position Historical Data

The historical data trend for Moleculin Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Ending Cash Position Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

10.74

15.17

70.90

43.15

23.55

Moleculin Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															43.15	37.27	32.17	24.58	23.55

Moleculin Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Moleculin Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	43.145	+	-19.595
	=	23.55

Moleculin Biotech's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	24.579	+	-1.029
	=	23.55

Moleculin Biotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (Moleculin Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

MOLA:Germany

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Executives

Jonathan P. Foster	officer: Exec. Vice President and CFO	2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp	director, 10 percent owner, officer: Chairman and Acting CEO	1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco	director	PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker	10 percent owner, officer: President and COO
Michael D Cannon	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth	officer: Chief Financial Officer	2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380